Multivariable analysis for risk factors for development of infections
| Variable . | n . | RR of infection (95% CI) . | P . |
|---|---|---|---|
| Any infection (bacterial/viral/fungal)* | |||
| Main effect variable | .0006 | ||
| RIC/NMA | 777 | 1.00 | |
| MAC | 978 | 1.28 (1.11-1.48) | |
| HCT–comorbidity index | <.0001 | ||
| 0 | 458 | 1.00 | |
| 1-2 | 400 | 1.14 (0.96-1.36) | .1318 |
| ≥3 | 499 | 1.19 (1.02-1.38) | .0261 |
| NA (before 2007) | 375 | 0.70 (0.57-0.86) | .0008 |
| Missing | 23 | 1.28 (0.77-2.14) | .3335 |
| Donor/recipient HLA match | <.0001 | ||
| HLA-identical related donor | 597 | 1.00 | |
| UCB | 257 | 1.81 (1.40-2.34) | <.0001 |
| Well-matched unrelated | 690 | 0.97 (0.80-1.18) | .7708 |
| Partially matched/mismatched unrelated | 167 | 1.19 (0.95-1.49) | .187 |
| Unrelated—match unknown | 44 | 1.68 (1.20-2.35) | .0024 |
| ATG/alemtuzumab peri-HCT | .0004 | ||
| No | 1208 | 1.00 | |
| Yes | 547 | 1.33 (1.13-1.55) | |
| Acute GVHD grades II-IV before infection | <.0001 | ||
| No | 1135 | 1.00 | |
| Yes | 620 | 1.53 (1.33-1.77) | |
| Bacterial infection | |||
| Main effect variable | <.0001 | ||
| RIC/NMA | 777 | 1.00 | |
| MAC | 978 | 1.44 (1.23-1.67) | |
| Donor/recipient HLA match | <.0001 | ||
| HLA-identical related donor | 597 | 1.00 | |
| UCB | 257 | 1.57 (1.27-1.95) | <.0001 |
| Well-matched unrelated | 690 | 0.90 (0.76 –1.08) | .2531 |
| Partially matched/mismatched unrelated | 167 | 1.00 (0.76-1.30) | .9752 |
| Unrelated—match unknown | 44 | 0.70 (0.41-1.20) | .1937 |
| Neutrophil engraftment before infection | .0009 | ||
| No | 396 | 1.00 | |
| Yes | 1359 | 0.60 (0.44-0.81) | |
| Viral infection before bacterial infection | <.0001 | ||
| No | 1323 | 1.00 | |
| Yes | 432 | 1.82 (1.46-2.26) | |
| Fungal infection before bacterial infection | .0007 | ||
| No | 1706 | 1.00 | |
| Yes | 49 | 2.13 (1.38-3.30) | |
| Viral infection* | |||
| Main effect variable | .9930 | ||
| RIC/NMA | 777 | 1.00 | |
| MAC | 978 | 1.00 (0.82-1.21) | |
| HCT–comorbidity index | .0001 | ||
| 0 | 458 | 1.00 | |
| 1-2 | 400 | 1.09 (0.85-1.40) | .5118 |
| ≥3 | 499 | 1.26 (1.03-1.55) | .0270 |
| NA (before 2007) | 375 | 0.62 (0.45-0.86) | .0036 |
| Missing | 23 | 1.45 (0.88-2.38) | .1495 |
| Donor/recipient HLA match | <.0001 | ||
| HLA-identical related donor | 597 | 1.00 | |
| UCB | 257 | 2.63 (2.06-3.35) | <.0001 |
| Well-matched unrelated | 690 | 1.19 (0.96-1.49) | .1152 |
| Partially matched/mismatched unrelated | 167 | 1.46 (1.10-1.93) | .0078 |
| Unrelated—match unknown | 44 | 2.50 (1.52-4.11) | .0003 |
| ATG/alemtuzumab peri-HCT, ≤39 d | <.0001 | ||
| No | 1208 | 1.00 | |
| Yes | 547 | 2.48(1.94-3.15) | |
| ATG/alemtuzumab peri-HCT, >39 d | .8328 | ||
| No | 1417 | 1.00 | |
| Yes | 338 | 1.03 (0.77-1.38) | |
| Acute GVHD grades II-IV before infection | <.0001 | ||
| No | 1116 | 1.00 | |
| Yes | 639 | 1.73 (1.46-2.06) | |
| Bacterial infection before viral infection | .0002 | ||
| No | 1140 | 1.00 | |
| Yes | 615 | 1.40 (1.18-1.67) | |
| Fungal infection | |||
| Main effect variable | .9696 | ||
| RIC/NMA | 777 | 1.00 | |
| MAC | 978 | 0.99 (0.64-1.54) | |
| Donor/recipient HLA match | .0226 | ||
| HLA-identical related donor | 597 | 1.00 | |
| UCB | 257 | 2.65 (1.41-5.00) | .0026 |
| Well-matched unrelated | 690 | 1.31 (0.72-2.38) | .3684 |
| Partially matched/mismatched unrelated | 167 | 1.49 (0.65-3.44) | .3467 |
| Unrelated—match unknown | 44 | 2.74 (0.92-8.15) | .0708 |
| Neutrophil engraftment before infection | .0053 | ||
| No | 65 | 1.00 | |
| Yes | 1690 | 0.37 (0.18-0.74) | |
| Bacterial infection before viral infection | .0119 | ||
| No | 1037 | 1.00 | |
| Yes | 718 | 1.81 (1.14-2.89) | |
| Viral infection before bacterial infection | .0038 | ||
| No | 1135 | 1.00 | |
| Yes | 620 | 2.17 (1.28-3.67) | |
| Variable . | n . | RR of infection (95% CI) . | P . |
|---|---|---|---|
| Any infection (bacterial/viral/fungal)* | |||
| Main effect variable | .0006 | ||
| RIC/NMA | 777 | 1.00 | |
| MAC | 978 | 1.28 (1.11-1.48) | |
| HCT–comorbidity index | <.0001 | ||
| 0 | 458 | 1.00 | |
| 1-2 | 400 | 1.14 (0.96-1.36) | .1318 |
| ≥3 | 499 | 1.19 (1.02-1.38) | .0261 |
| NA (before 2007) | 375 | 0.70 (0.57-0.86) | .0008 |
| Missing | 23 | 1.28 (0.77-2.14) | .3335 |
| Donor/recipient HLA match | <.0001 | ||
| HLA-identical related donor | 597 | 1.00 | |
| UCB | 257 | 1.81 (1.40-2.34) | <.0001 |
| Well-matched unrelated | 690 | 0.97 (0.80-1.18) | .7708 |
| Partially matched/mismatched unrelated | 167 | 1.19 (0.95-1.49) | .187 |
| Unrelated—match unknown | 44 | 1.68 (1.20-2.35) | .0024 |
| ATG/alemtuzumab peri-HCT | .0004 | ||
| No | 1208 | 1.00 | |
| Yes | 547 | 1.33 (1.13-1.55) | |
| Acute GVHD grades II-IV before infection | <.0001 | ||
| No | 1135 | 1.00 | |
| Yes | 620 | 1.53 (1.33-1.77) | |
| Bacterial infection | |||
| Main effect variable | <.0001 | ||
| RIC/NMA | 777 | 1.00 | |
| MAC | 978 | 1.44 (1.23-1.67) | |
| Donor/recipient HLA match | <.0001 | ||
| HLA-identical related donor | 597 | 1.00 | |
| UCB | 257 | 1.57 (1.27-1.95) | <.0001 |
| Well-matched unrelated | 690 | 0.90 (0.76 –1.08) | .2531 |
| Partially matched/mismatched unrelated | 167 | 1.00 (0.76-1.30) | .9752 |
| Unrelated—match unknown | 44 | 0.70 (0.41-1.20) | .1937 |
| Neutrophil engraftment before infection | .0009 | ||
| No | 396 | 1.00 | |
| Yes | 1359 | 0.60 (0.44-0.81) | |
| Viral infection before bacterial infection | <.0001 | ||
| No | 1323 | 1.00 | |
| Yes | 432 | 1.82 (1.46-2.26) | |
| Fungal infection before bacterial infection | .0007 | ||
| No | 1706 | 1.00 | |
| Yes | 49 | 2.13 (1.38-3.30) | |
| Viral infection* | |||
| Main effect variable | .9930 | ||
| RIC/NMA | 777 | 1.00 | |
| MAC | 978 | 1.00 (0.82-1.21) | |
| HCT–comorbidity index | .0001 | ||
| 0 | 458 | 1.00 | |
| 1-2 | 400 | 1.09 (0.85-1.40) | .5118 |
| ≥3 | 499 | 1.26 (1.03-1.55) | .0270 |
| NA (before 2007) | 375 | 0.62 (0.45-0.86) | .0036 |
| Missing | 23 | 1.45 (0.88-2.38) | .1495 |
| Donor/recipient HLA match | <.0001 | ||
| HLA-identical related donor | 597 | 1.00 | |
| UCB | 257 | 2.63 (2.06-3.35) | <.0001 |
| Well-matched unrelated | 690 | 1.19 (0.96-1.49) | .1152 |
| Partially matched/mismatched unrelated | 167 | 1.46 (1.10-1.93) | .0078 |
| Unrelated—match unknown | 44 | 2.50 (1.52-4.11) | .0003 |
| ATG/alemtuzumab peri-HCT, ≤39 d | <.0001 | ||
| No | 1208 | 1.00 | |
| Yes | 547 | 2.48(1.94-3.15) | |
| ATG/alemtuzumab peri-HCT, >39 d | .8328 | ||
| No | 1417 | 1.00 | |
| Yes | 338 | 1.03 (0.77-1.38) | |
| Acute GVHD grades II-IV before infection | <.0001 | ||
| No | 1116 | 1.00 | |
| Yes | 639 | 1.73 (1.46-2.06) | |
| Bacterial infection before viral infection | .0002 | ||
| No | 1140 | 1.00 | |
| Yes | 615 | 1.40 (1.18-1.67) | |
| Fungal infection | |||
| Main effect variable | .9696 | ||
| RIC/NMA | 777 | 1.00 | |
| MAC | 978 | 0.99 (0.64-1.54) | |
| Donor/recipient HLA match | .0226 | ||
| HLA-identical related donor | 597 | 1.00 | |
| UCB | 257 | 2.65 (1.41-5.00) | .0026 |
| Well-matched unrelated | 690 | 1.31 (0.72-2.38) | .3684 |
| Partially matched/mismatched unrelated | 167 | 1.49 (0.65-3.44) | .3467 |
| Unrelated—match unknown | 44 | 2.74 (0.92-8.15) | .0708 |
| Neutrophil engraftment before infection | .0053 | ||
| No | 65 | 1.00 | |
| Yes | 1690 | 0.37 (0.18-0.74) | |
| Bacterial infection before viral infection | .0119 | ||
| No | 1037 | 1.00 | |
| Yes | 718 | 1.81 (1.14-2.89) | |
| Viral infection before bacterial infection | .0038 | ||
| No | 1135 | 1.00 | |
| Yes | 620 | 2.17 (1.28-3.67) | |
Center effect identified.